EUVIMEDScopri EUVIMED
Video/AudioOpen access

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery

Anna E Christenson, Nikita S Divekar, Mitzi G Hernández Zamora, Carolyn D Nguyen, James K Nuñez

Journal of Visualized Experiments · 2025

DOI: 10.3791/68089 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2025. Written by Anna E Christenson and 4 co-authors. Institution: Department of Molecular and Cell Biology, University of California, Berkeley. Major MEDLINE topics: Plasmids, RNA, Messenger, Transfection, DNA. Cited 2 times so far (Crossref); 55 references. The full text is freely available in PubMed Central. Funded by: NIGMS NIH HHS.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Epigenetics refers to chemical modifications of histone proteins and DNA that can regulate the expression of genes. The human epigenome is altered dynamically during cell differentiation and aging, and many diseases are associated with aberrant epigenome patterning. Recent advances in CRISPR have led to the development of programmable tools to edit epigenetic modifications at targeted genomic loci, enabling precise rewriting of epigenetic modifications in human cells. CRISPR-based epigenome editors rely on catalytically dead Cas9 coupled with epigenetic modifiers that ultimately result in programmed repression or activation of targeted genes in mammalian genomes. Unlike traditional genome editing methods, epigenome editing does not require DNA breaks or changes in the human genome sequence and thus serves as a safer alternative to control gene expression. In this protocol, we highlight two different methods to perform dCas9-mediated epigenome editing in human cell lines using plasmid DNA transfections and nucleofection of mRNAs encoding CRISPR epigenome editors. We demonstrate programmable epigenome editing to transiently repress genes using CRISPR interference (CRISPRi) and for silencing genes durably for many weeks using CRISPRoff, a fusion of dCas9 to the KRAB domain and de novo DNA methyltransferase complex. We also provide guidance on quantitative methods to measure successful epigenome editing of target genes and key considerations on which epigenome editing tool to use, depending on experimental criteria.

Subjects

MeSH terms (MEDLINE)

PlasmidsRNA, MessengerTransfectionDNAGene EditingCRISPR-Cas SystemsEpigenomeClustered Regularly Interspaced Short Palindromic RepeatsHumansEpigenome Editing

Substances

RNA, MessengerDNA

Authors and institutions

  • Department of Molecular and Cell Biology, University of California, Berkeley.
  • Department of Molecular and Cell Biology, University of California, Berkeley; Chan Zuckerberg Biohub - San Francisco; jamesnunez@berkeley.edu.

Funding

  • NIGMS NIH HHS

Cite

APA

Christenson, A. E., Divekar, N. S., Hernández Zamora, M. G., Nguyen, C. D., & Nuñez, J. K. (2025). CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery. Journal of Visualized Experiments. https://doi.org/10.3791/68089

Vancouver

Christenson AE, Divekar NS, Hernández Zamora MG, Nguyen CD, Nuñez JK. CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery. Journal of Visualized Experiments. 2025. doi:10.3791/68089

BibTeX
@article{Christenson2025,
  author = {Christenson, Anna E and Divekar, Nikita S and Hernández Zamora, Mitzi G and Nguyen, Carolyn D and Nuñez, James K},
  title = {CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery},
  journal = {Journal of Visualized Experiments},
  year = {2025},
  doi = {10.3791/68089}
}
Start for free →